secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021752
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency reports Q1 net loss $19.5M; cash $66.7M, debt prepaid; MS program on track for 2024
--------------------------------------------------------------------------------

- Net loss of $19.5M vs $23.4M in Q1 2022; R&D expenses $11.4M, G&A $9.2M.
- Cash, equivalents and marketable securities $66.7M at March 31, 2023; all outstanding loans prepaid in April.
- MS remyelination program on track for clinical start in H1 2024; novel NCEs show robust in vivo remyelination.
- Preclinical data show statistical improvements in MRI white matter volume and oligodendrocyte differentiation across species.
- Company exploring strategic options to create shareholder value; restructuring extends cash runway into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/0000950170-23-021752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/freq-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer